Actively Recruiting
Open-Label Study of Human Secretin Injection on Pancreatic Fluid Composition in Healthy Adults
Led by Mayo Clinic · Updated on 2026-04-28
24
Participants Needed
1
Research Sites
52 weeks
Total Duration
On this page
Sponsors
M
Mayo Clinic
Lead Sponsor
C
ChiRhoClin, Inc.
Collaborating Sponsor
AI-Summary
What this Trial Is About
This research aims to study the effect of human secretin injection on the composition of pancreatic fluid in healthy adults undergoing endoscopic ultrasound for reasons unrelated to pancreatic disease. The study focuses on understanding how secretin stimulates pancreatic fluid secretion and analyzes changes in fluid components such as bicarbonate, sodium, potassium, and chloride over time. Participants will receive an intravenous dose of human synthetic secretin at 0.2 micrograms per kilogram during the endoscopic ultrasound procedure. Pancreatic fluid will be collected from the duodenum at four time points: 5, 10, 15, and 20 minutes after secretin administration. The study groups will be divided into three age categories: 18-35, 35-45, and 46 years and older. Participants will be involved during the endoscopic ultrasound procedure where fluid samples are collected for analysis. Researchers will measure the levels of bicarbonate, sodium, potassium, and chloride in the pancreatic fluid at the specified intervals after secretin injection. The study will monitor the fluid composition changes to better understand pancreatic function. The total duration of participation aligns with the timing of the ultrasound and sample collection process.
CONDITIONS
Brief Title
A Study Of Effect Of Secretin For In Injection (Chirostim) On Pancreatic Fluid Composition In Healthy Subjects
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male or non-pregnant female
- Age between 18 and 80 years
- In good health with ASA Class 3 or below
- Willing and able to provide informed consent
- Undergoing endoscopic ultrasound for a non-pancreatic reason
You will not qualify if you...
- History of pancreatitis or other pancreatic diseases such as cysts or masses
- History of inflammatory bowel disease
- History of vagotomy
- History of surgically altered upper gastrointestinal anatomy like gastric bypass or Billroth I/II
- History of liver disease
- Pregnant or nursing women
- Regular use of anticholinergic medications
- Consuming more than 2 alcoholic drinks daily
- Current cigarette smokers
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Single day
Participants receive a single intravenous dose of human secretin during an endoscopic ultrasound. Pancreatic fluid is collected at 5, 10, 15, and 20 minutes after secretin administration to analyze pancreatic fluid composition.
1 treatment visit (in-person)
Trial Site Locations
Total: 1 location
1
Mayo Clinic in Rochester
Rochester, Minnesota, United States, 55905
Actively Recruiting
Research Team
L
Liz Lemke
S
Samuel Han, MD
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
OTHER
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here